Approval of antiretroviral drug TDF/FTC

The US Food and Drug Administration (FDA) announced the approval of the antiretroviral drug TDF/FTC (brand name Truvada) for use as pre-exposure prophylaxis (PrEP) among sexually active adult men and women in the US. This approval paves the way for daily oral PrEP using TDF/FTC to be introduced as HIV prevention in the US. 

Read the article…>